Compare Johnson & Johnson (JNJ) vs Kinross Gold Corporation (KGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Kinross Gold Corporation — how do they compare? Johnson & Johnson trades at $261.54 (market cap $618.09B), while Kinross Gold Corporation trades at $23.7 (market cap $27.62B). The key difference: Johnson & Johnson is far larger — about 22.4× Kinross Gold Corporation's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Kinross Gold Corporation for 53 Days on average.
| JNJ | KGC | |
|---|---|---|
Market Cap | $618.09B | $27.62B |
Volume | 6,050,983 | 6,347,266 |
Sector | Health | Basic Materials |
52-Week High | $278.43 | $38.06 |
52-Week Low | $186.00 | $22.47 |
Typical Hold Time | 129 Days | 53 Days |
Enterprise Value | $646.37B | $25.70B |
Dividend Yield | 2.09% | 0.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Kinross Gold (KGC) trades at $23.74, up 2.42% with strong fundamentals including 37.52% net margin and 36.95% ROE. The stock shows bearish technical signals despite recent earnings beats and analyst consensus of $38.80 price target. Recent news highlights production guidance cuts and increased shareholder returns, creating mixed sentiment.
KGC offers attractive valuation with 8.87 P/E but faces near-term headwinds from production issues. The company maintains strong cash flow growth and balance sheet strength, though legal investigations and operational challenges present risks. Wall Street maintains bullish long-term outlook with 59% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Kinross Gold Corporation
Kinross Gold is a Canada-based senior gold producer, producing roughly 2.4 million gold equivalent ounces in 2020. The company had 30 million ounces of proven and probable gold reserves and 59 million ounces of silver reserves at the end of 2020. It operates mines and focuses its greenfield and brownfield exploration in the Americas, West Africa, and Russia. The company has historically used acquisitions to fuel expansion into new regions and production growth.
Read more on KGC →
